

Sven Rottenberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8160162/publications.pdf>

Version: 2024-02-01

80
papers

9,720
citations

87888

38
h-index

66911

78
g-index

83
all docs

83
docs citations

83
times ranked

13768
citing authors

#	ARTICLE	IF	CITATIONS
1	A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity. <i>Cell</i> , 2018, 172, 373-386.e10.	28.9	1,201
2	High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 17079-17084.	7.1	854
3	Replication fork stability confers chemoresistance in BRCA-deficient cells. <i>Nature</i> , 2016, 535, 382-387.	27.8	685
4	REV7 counteracts DNA double-strand break resection and affects PARP inhibition. <i>Nature</i> , 2015, 521, 541-544.	27.8	487
5	The rediscovery of platinum-based cancer therapy. <i>Nature Reviews Cancer</i> , 2021, 21, 37-50.	28.4	452
6	The shieldin complex mediates 53BP1-dependent DNA repair. <i>Nature</i> , 2018, 560, 117-121.	27.8	445
7	PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer. <i>Cancer Discovery</i> , 2019, 9, 722-737.	9.4	433
8	Loss of 53BP1 Causes PARP Inhibitor Resistance in <i>Brca1</i> -Mutated Mouse Mammary Tumors. <i>Cancer Discovery</i> , 2013, 3, 68-81.	9.4	428
9	Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. <i>Nature Communications</i> , 2013, 4, 1908.	12.8	310
10	Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 12117-12122.	7.1	279
11	EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation. <i>Nature Cell Biology</i> , 2017, 19, 1371-1378.	10.3	257
12	Selective Loss of PARC Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality. <i>Cancer Cell</i> , 2018, 33, 1078-1093.e12.	16.8	238
13	BRCA1 RING Function Is Essential for Tumor Suppression but Dispensable for Therapy Resistance. <i>Cancer Cell</i> , 2011, 20, 797-809.	16.8	228
14	53BP1 cooperation with the REV7–shieldin complex underpins DNA structure-specific NHEJ. <i>Nature</i> , 2018, 560, 122-127.	27.8	222
15	Subunit composition of VRAC channels determines substrate specificity and cellular resistance to P-glycoprotein-based anti-cancer drugs. <i>EMBO Journal</i> , 2015, 34, 2993-3008.	7.8	209
16	How do real tumors become resistant to cisplatin?. <i>Cell Cycle</i> , 2008, 7, 1353-1359.	2.6	185
17	CopywriteR: DNA copy number detection from off-target sequence data. <i>Genome Biology</i> , 2015, 16, 49.	8.8	183
18	Inhibition of apoptosis by intracellular protozoan parasites. <i>International Journal for Parasitology</i> , 2001, 31, 1166-1176.	3.1	161

#	ARTICLE	IF	CITATIONS
19	Hijacking of Host Cell IKK Signalosomes by the Transforming Parasite <i>Theileria</i> . <i>Science</i> , 2002, 298, 1033-1036.	12.6	126
20	HELB Is a Feedback Inhibitor of DNA End Resection. <i>Molecular Cell</i> , 2016, 61, 405-418.	9.7	119
21	BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance. <i>Nature Methods</i> , 2018, 15, 134-140.	19.0	110
22	The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells. <i>Cell Reports</i> , 2018, 23, 2107-2118.	6.4	110
23	Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 8409-8414.	7.1	106
24	BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1. <i>Journal of Clinical Investigation</i> , 2016, 126, 2903-2918.	8.2	105
25	6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance. <i>Cancer Research</i> , 2010, 70, 6268-6276.	0.9	102
26	What Makes Tumors Multidrug Resistant?. <i>Cell Cycle</i> , 2007, 6, 2782-2787.	2.6	97
27	Moderate Increase in <i>Mdr1a/1b</i> Expression Causes <i>In vivo</i> Resistance to Doxorubicin in a Mouse Model for Hereditary Breast Cancer. <i>Cancer Research</i> , 2009, 69, 6396-6404.	0.9	88
28	Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells. <i>Nature Communications</i> , 2017, 8, 15981.	12.8	83
29	Sensitivity and Acquired Resistance of BRCA1;p53-Deficient Mouse Mammary Tumors to the Topoisomerase I Inhibitor Topotecan. <i>Cancer Research</i> , 2010, 70, 1700-1710.	0.9	76
30	The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity. <i>Nature Communications</i> , 2018, 9, 5406.	12.8	74
31	The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models. <i>Cancer Research</i> , 2016, 76, 6084-6094.	0.9	73
32	Further Evidence for BRCA1 Communication with the Inactive X Chromosome. <i>Cell</i> , 2007, 128, 991-1002.	28.9	72
33	Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response. <i>Genome Medicine</i> , 2018, 10, 101.	8.2	72
34	<i>Theileria</i> -induced leukocyte transformation. <i>Current Opinion in Microbiology</i> , 2003, 6, 377-382.	5.1	66
35	Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas. <i>Cell Reports</i> , 2018, 23, 100-111.	6.4	60
36	Impact of Intertumoral Heterogeneity on Predicting Chemotherapy Response of BRCA1-Deficient Mammary Tumors. <i>Cancer Research</i> , 2012, 72, 2350-2361.	0.9	48

#	ARTICLE	IF	CITATIONS
37	BRCA2-Deficient Sarcomatoid Mammary Tumors Exhibit Multidrug Resistance. <i>Cancer Research</i> , 2015, 75, 732-741.	0.9	47
38	Resistance to PARP Inhibitors: Lessons from Preclinical Models of BRCA-Associated Cancer. <i>Annual Review of Cancer Biology</i> , 2019, 3, 235-254.	4.5	47
39	Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors. <i>Cancer Research</i> , 2019, 79, 452-460.	0.9	42
40	Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps. <i>Molecular Cell</i> , 2021, 81, 4692-4708.e9.	9.7	40
41	Minimal residual disease in cancer therapy “ Small things make all the difference. <i>Drug Resistance Updates</i> , 2015, 21-22, 1-10.	14.4	34
42	Cancer cell death by programmed necrosis?. <i>Drug Resistance Updates</i> , 2004, 7, 321-324.	14.4	33
43	Drug resistance in the mouse cancer clinic. <i>Drug Resistance Updates</i> , 2012, 15, 81-89.	14.4	33
44	New tools for old drugs: Functional genetic screens to optimize current chemotherapy. <i>Drug Resistance Updates</i> , 2018, 36, 30-46.	14.4	33
45	Modeling therapy resistance in genetically engineered mouse cancer models. <i>Drug Resistance Updates</i> , 2008, 11, 51-60.	14.4	29
46	Functional Radiogenetic Profiling Implicates ERCC6L2 in Non-homologous End Joining. <i>Cell Reports</i> , 2020, 32, 108068.	6.4	29
47	Therapeutic options for triple-negative breast cancers with defective homologous recombination. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2009, 1796, 266-280.	7.4	28
48	Ritonavir inhibits intratumoral docetaxel metabolism and enhances docetaxel antitumor activity in an immunocompetent mouse breast cancer model. <i>International Journal of Cancer</i> , 2016, 138, 758-769.	5.1	26
49	Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivo. <i>Cell Cycle</i> , 2010, 9, 3804-3815.	2.6	24
50	EZN-2208 (PEG-SN38) Overcomes ABCG2-Mediated Topotecan Resistance in BRCA1-Deficient Mouse Mammary Tumors. <i>PLoS ONE</i> , 2012, 7, e45248.	2.5	24
51	Proteomics of Genetically Engineered Mouse Mammary Tumors Identifies Fatty Acid Metabolism Members as Potential Predictive Markers for Cisplatin Resistance. <i>Molecular and Cellular Proteomics</i> , 2013, 12, 1319-1334.	3.8	24
52	Proteomics of Mouse BRCA1-deficient Mammary Tumors Identifies DNA Repair Proteins with Potential Diagnostic and Prognostic Value in Human Breast Cancer. <i>Molecular and Cellular Proteomics</i> , 2012, 11, M111.013334-1-M111.013334-19.	3.8	23
53	Intraoperative <i>ex vivo</i> photoacoustic nodal staging in a rat model using a clinical superparamagnetic iron oxide nanoparticle dispersion. <i>Journal of Biophotonics</i> , 2013, 6, 493-504.	2.3	22
54	Identifying subgroup markers in heterogeneous populations. <i>Nucleic Acids Research</i> , 2013, 41, e200-e200.	14.5	21

#	ARTICLE	IF	CITATIONS
55	Selected Alkylating Agents Can Overcome Drug Tolerance of G0-like Tumor Cells and Eradicate BRCA1-Deficient Mammary Tumors in Mice. <i>Clinical Cancer Research</i> , 2017, 23, 7020-7033.	7.0	20
56	Noninvasive functional imaging of P-glycoprotein-mediated doxorubicin resistance in a mouse model of hereditary breast cancer to predict response, and assign P-gp inhibitor sensitivity. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 406-412.	6.4	19
57	Studying PAR-Dependent Chromatin Remodeling to Tackle PARPi Resistance. <i>Trends in Molecular Medicine</i> , 2021, 27, 630-642.	6.7	18
58	Monitoring of Tumor Response to Cisplatin Using Optical Spectroscopy. <i>Translational Oncology</i> , 2014, 7, 230-239.	3.7	17
59	Increased levels of choline metabolites are an early marker of docetaxel treatment response in BRCA1-mutated mouse mammary tumors: an assessment by ex vivo proton magnetic resonance spectroscopy. <i>Journal of Translational Medicine</i> , 2015, 13, 114.	4.4	17
60	Questioning the value of 99mTc-HYNIC-annexin V based response monitoring after docetaxel treatment in a mouse model for hereditary breast cancer. <i>Applied Radiation and Isotopes</i> , 2011, 69, 656-662.	1.5	16
61	Real-Time In Vivo Characterization of Primary Liver Tumors With Diffuse Optical Spectroscopy During Percutaneous Needle Interventions. <i>Investigative Radiology</i> , 2015, 50, 443-448.	6.2	16
62	Identification and characterisation of a <i>Theileria annulata</i> proline-rich microtubule and SH3 domain-interacting protein (TaMISHIP) that forms a complex with CLASP1, EB1, and CD2AP at the schizont surface. <i>Cellular Microbiology</i> , 2018, 20, e12838.	2.1	16
63	Characterization of the bovine Î²B kinases (IKK)Î± and IKKÎ², the regulatory subunit NEMO and their substrate Î²BÎ±. <i>Gene</i> , 2002, 299, 293-300.	2.2	14
64	Secretome proteomics reveals candidate non-invasive biomarkers of <i>BRCA1</i> deficiency in breast cancer. <i>Oncotarget</i> , 2016, 7, 63537-63548.	1.8	14
65	Meiotic Genes and DNA Double Strand Break Repair in Cancer. <i>Frontiers in Genetics</i> , 2022, 13, 831620.	2.3	14
66	MEK inhibition as a strategy for targeting residual breast cancer cells with low DUSP4 expression. <i>Breast Cancer Research</i> , 2012, 14, 324.	5.0	13
67	Replication Fork Remodeling and Therapy Escape in DNA Damage Response-Deficient Cancers. <i>Frontiers in Oncology</i> , 2020, 10, 670.	2.8	13
68	Lack of ABCG2 Shortens Latency of BRCA1-Deficient Mammary Tumors and This Is Not Affected by Genistein or Resveratrol. <i>Cancer Prevention Research</i> , 2012, 5, 1053-1060.	1.5	12
69	Haploid genetic screens identify genetic vulnerabilities to microtubule-targeting agents. <i>Molecular Oncology</i> , 2018, 12, 953-971.	4.6	12
70	Genetic Dissection of Cancer Development, Therapy Response, and Resistance in Mouse Models of Breast Cancer. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2016, 81, 141-150.	1.1	10
71	Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model. <i>Oncotarget</i> , 2017, 8, 87638-87646.	1.8	10
72	Studying Drug Resistance Using Genetically Engineered Mouse Models for Breast Cancer. <i>Methods in Molecular Biology</i> , 2010, 596, 33-45.	0.9	9

#	ARTICLE	IF	CITATIONS
73	Towards a national strategy for digital pathology in Switzerland. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 481, 647-652.	2.8	7
74	Development of a Tumour Growth Inhibition Model to Elucidate the Effects of Ritonavir on Intratumoural Metabolism and Anti-tumour Effect of Docetaxel in a Mouse Model for Hereditary Breast Cancer. AAPS Journal, 2016, 18, 362-371.	4.4	4
75	Immunohistochemical Analysis of Programmed Death-Ligand 1 Expression in Equine Sarcoids. Journal of Equine Veterinary Science, 2021, 97, 103338.	0.9	3
76	Photoacoustic staging of nodal metastases using SPIOs: Comparison between in vivo, inÂtoto and ex vivo imaging in a rat model. Biomedical Spectroscopy and Imaging, 2017, 5, 71-87.	1.2	1
77	Studying cancer drug resistance using BRCA-deficient mouse mammary tumor organoids. Protocol Exchange, 0, , .	0.3	1
78	Functional genetic dropout screens and in vivo validation of candidate therapeutic targets using mouse mammary tumoroids. STAR Protocols, 2022, 3, 101132.	1.2	1
79	Abstract A14: Lack of tumor eradication of chemotherapy-sensitive BRCA1;p53-deficient mouse mammary tumors. , 2010, , .		0
80	PARP Inhibitor Resistanceâ€”What Is Beyond BRCA1 or BRCA2 Restoration?. Cancer Drug Discovery and Development, 2015, , 453-471.	0.4	0